Observer Blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK576389A With Various Formulations in Adults Aged 65 Years and Above.
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2018
At a glance
- Drugs GSK 576389A (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 29 Jan 2008 Status changed from recruiting to completed, in accordance with clinicaltrials.gov.
- 05 Nov 2007 New trial record.